151 related articles for article (PubMed ID: 31583878)
1. Pseudovitelliform maculopathy secondary to BRAF and MEK inhibitors in a patient with metastasic melanoma.
Alba-Linero C; Rocha De Lossada C; Delgado-Fernández AS; Jódar-Márquez M; Rodríguez Calvo De Mora M; Berciano-Guerrero MA
J Biol Regul Homeost Agents; 2019 September-October,; 33(5):1497-1500. PubMed ID: 31583878
[No Abstract] [Full Text] [Related]
2. Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
Morgado-Carrasco D; Moreno-Rivera N; Fustà-Novell X; García-Herrera A; Carrera C; Puig S
Melanoma Res; 2018 Jun; 28(3):256-257. PubMed ID: 29683894
[No Abstract] [Full Text] [Related]
3. Reversible BRAF inhibitor-induced acute exudative paraneoplastic polymorphous vitelliform maculopathy.
Samalia P; Niederer R
N Z Med J; 2021 Aug; 134(1540):89-92. PubMed ID: 34482393
[No Abstract] [Full Text] [Related]
4. Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare.
Ibrahim T; Routier E; Weill A; Baz M; Robert C
Eur J Cancer; 2017 Sep; 82():25-26. PubMed ID: 28646770
[No Abstract] [Full Text] [Related]
5. Use of proton pump inhibitors in people taking BRAF/MEK inhibitors for metastatic melanoma.
Br J Dermatol; 2023 Mar; 188(4):e29. PubMed ID: 36994709
[No Abstract] [Full Text] [Related]
6. Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report.
Quéreux G; Herbreteau G; Knol AC; Vallée A; Khammari A; Théoleyre S; Saint-Jean M; Dréno B; Denis MG
BMC Res Notes; 2017 Jul; 10(1):320. PubMed ID: 28743309
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
8. Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting.
Tétu P; Baroudjian B; Lebbe C
Curr Opin Oncol; 2020 Mar; 32(2):85-90. PubMed ID: 31895121
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?
Sloot S; Fedorenko IV; Smalley KS; Gibney GT
Expert Opin Pharmacother; 2014 Apr; 15(5):589-92. PubMed ID: 24456413
[TBL] [Abstract][Full Text] [Related]
11. Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors.
Devic P; Amini-Adle M; Camdessanché JP; Dalle S
Eur J Cancer; 2017 Jun; 78():103-104. PubMed ID: 28432982
[No Abstract] [Full Text] [Related]
12. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
13. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
14. Melanoma Treatments: Advances and Mechanisms.
Marzuka A; Huang L; Theodosakis N; Bosenberg M
J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
[TBL] [Abstract][Full Text] [Related]
15. Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.
Krayem M; Najem A; Journe F; Morandini R; Sales F; Awada A; Ghanem GE
Oncotarget; 2024 Jun; 15():354. PubMed ID: 38829662
[No Abstract] [Full Text] [Related]
16. The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases.
Smalley KSM; Forsyth PA
Pharmacol Res; 2018 Sep; 135():265-267. PubMed ID: 29146209
[No Abstract] [Full Text] [Related]
17. Hemorrhage of liver and bone metastases as a result of rapid response to dual BRAF/MEK inhibition in metastatic melanoma: a case report.
Loyson T; Werbrouck E; Punie K; Bonne L; Vandecaveye V; Bechter O
Melanoma Res; 2018 Apr; 28(2):147-150. PubMed ID: 29215399
[TBL] [Abstract][Full Text] [Related]
18. [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].
Gutzmer R; Hassel JC; Kähler KC; Loquai C; Mössner R; Ugurel S; Zimmer L; der das Ado FK
Hautarzt; 2014 Jul; 65(7):582-9. PubMed ID: 24903029
[TBL] [Abstract][Full Text] [Related]
19. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
[TBL] [Abstract][Full Text] [Related]
20. Is it good or bad to find a BRAF mutation?
Flaherty KT
J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
[No Abstract] [Full Text] [Related]
[Next] [New Search]
